Stevanato Q2 revenue climbs 8%, beats estimates
Overview
Stevanato Q2 2025 revenue grows 8% yr/yr, beating analysts' expectations
Net income for Q2 beats analyst estimates
Company maintains fiscal 2025 guidance, indicating confidence in strategic plans
Outlook
Stevanato maintains fiscal 2025 revenue guidance of €1.160 bln to €1.190 bln
Company expects 2025 adjusted EBITDA between €288.5 mln and €301.8 mln
Stevanato forecasts 2025 adjusted diluted EPS of €0.50 to €0.54
Company says demand driven by pharmaceutical innovation and biologics
Result Drivers
BDS SEGMENT GROWTH - 10% increase in Biopharmaceutical and Diagnostic Solutions segment revenue driven by high-value syringes and increased production capacity at Latina and Fishers facilities
HIGH-VALUE SOLUTIONS - High-value solutions, including syringes, EZ-fill cartridges, and vials, represented 42% of total revenue, contributing significantly to qtr growth
ENGINEERING SEGMENT DECLINE - 2% revenue decline in Engineering Segment due to lower revenue from glass converting and unfavorable project mix
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | EUR 280 mln | EUR 268.30 mln (9 Analysts) |
Q2 Net Income | Beat | EUR 29.70 mln | EUR 29.20 mln (9 Analysts) |
Q2 Operating Income | Beat | EUR 41.40 mln | EUR 40 mln (9 Analysts) |
Q2 Pretax Profit | Beat | EUR 39.10 mln | EUR 37.30 mln (7 Analysts) |
Q2 Basic EPS | EUR 0.11 | ||
Q2 Gross Profit | EUR 78.60 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Stevanato Group SpA is $28.00, about 8.6% above its August 4 closing price of $25.58
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 32 three months ago
Press Release:
